Plain-English translation of NCT05019885 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is an early-stage study testing whether ketamine — a medication normally used in anesthesia — might help people whose epilepsy hasn't responded to standard anti-seizure drugs. Researchers will give participants small doses of ketamine through an IV (intravenous line) three times a week for two weeks, and then track how many seizures they have over the following months. The study will also look at how the medication affects mood and overall quality of life.
About one-third of people with epilepsy don't respond well to the medications currently available, and they need new treatment options. This medication has shown promise in early research for helping seizures, so researchers want to see if it could be a new tool for patients who haven't benefited from existing treatments.
You likely qualify if…
You likely don't qualify if…
You'll start with a 4-week screening phase where you track your seizures in a diary. If you qualify, you'll come to the clinic three times a week (Monday, Wednesday, Friday) for two weeks to receive the medication through an IV line — each infusion takes about 40 minutes. After treatment ends, you'll have several follow-up visits and phone calls over the next few months (weeks 7 through 18) so researchers can check on your health, count your seizures, and assess any side effects or mood changes.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States